Phosphoantigen presentation by macrophages to mycobacterium tuberculosis--reactive Vgamma9Vdelta2+ T cells: modulation by chloroquine.
Vgamma9Vdelta2+ T cells (gammadelta T cells) are activated by Mycobacterium tuberculosis and recognize mycobacterial nonpeptide phosphoantigens. The role of antigen-presenting cells in the processing and presentation of phosphoantigens to Vgamma9Vdelta2+ T cells is not understood. We analyzed the role of macrophages for activation of gammadelta T cells by a new synthetic phosphoantigen bromohydrin pyrophosphate (BrHPP) and M. tuberculosis. Macrophages greatly increased gammadelta T-cell activation by both BrHPP and M. tuberculosis. Fixation of macrophages before infection demonstrated that uptake of M. tuberculosis was required for presentation to gammadelta T cells. Antigens of M. tuberculosis remained stably associated with macrophage surface and were not removed by paraformaldehyde fixation or washing. Macrophages processed M. tuberculosis for gammadelta T cells through a brefeldin A-insensitive pathway, suggesting that transport through the endoplasmic reticulum and Golgi complex of a putative presenting molecule is not important in the early processing of M. tuberculosis antigens for gammadelta T cells. Processing of M. tuberculosis was not eliminated by chloroquine, indicating that processing of gammadelta antigens is not dependent on acidic pH in the lysosomes. Chloroquine treatment of BrHPP-pulsed macrophages increased activation of gammadelta T cells. Ammonium chloride treatment of macrophages did not increase reactivity of gammadelta T cells to BrHPP, indicating that the effect of chloroquine was independent of pH changes in endosomes. Chloroquine, by inhibiting membrane traffic, may increase association and retention of phosphoantigens with cell surface membrane molecules on macrophages.
Department of Medicine, Case Western Reserve University and University Hospitals of Cleveland, Ohio 44106, USA. rxr38@po.cwru.edu
Roxana E
RE
Rojas
Martha
M
Torres
Jean-Jacques
JJ
Fournié
Clifford V
CV
Harding
W Henry
WH
Boom
D000328:Adult; D017951:Antigen Presentation; D000938:Antigen-Presenting Cells / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology*; D020126:Brefeldin A / Q000494:pharmacology; D002455:Cell Division; D002738:Chloroquine / Q000494:pharmacology*; D011756:Diphosphates / Q000494:pharmacology; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000276:immunology; D008264:Macrophages / Q000276:immunology*; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D010750:Phosphoproteins / Q000276:immunology*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
D000942:Antigens, Bacterial; D011756:Diphosphates; D007376:Interleukin-2; D010750:Phosphoproteins; D011500:Protein Synthesis Inhibitors; D016692:Receptors, Antigen, T-Cell, gamma-delta; C429553:bromohydrin pyrophosphate; D020126:Brefeldin A; D007371:Interferon-gamma; D002738:Chloroquine